Followed 129 TimesTop FollowedTrending NewsTrending NewsNYSE:LLY Eli Lilly and Company (LLY) Stock Price, News & Analysis $988.76 -16.16 (-1.61%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$985.00 -3.76 (-0.38%) As of 04:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eli Lilly and Company Stock (NYSE:LLY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eli Lilly and Company alerts:Sign Up Key Stats Today's Range$978.87▼$1,003.0050-Day Range$851.65▼$1,014.9352-Week Range$623.78▼$1,133.95Volume2.01 million shsAverage Volume3.46 million shsMarket Capitalization$931.15 billionP/E Ratio35.12Dividend Yield0.70%Price Target$1,218.33Consensus RatingModerate Buy Company Overview Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A. Ricks. Lilly’s core activities center on discovery and development of small-molecule and biologic therapies across multiple therapeutic areas, including diabetes and metabolic disease, oncology, neuroscience, immunology and pain. Its commercial portfolio includes longstanding and well-known medicines as well as newer specialty products; examples of medicines associated with the company include Humalog (insulin), duloxetine (Cymbalta), fluoxetine (Prozac), the GLP-1/GIP receptor-directed agent tirzepatide (marketed for type 2 diabetes) and a range of oncology and migraine treatments such as Alimta, Verzenio and Emgality. The company combines internal discovery programs with external collaborations and licensing arrangements to broaden its pipeline and commercial reach. Research and development is a central focus for Lilly, with substantial investment in clinical development, regulatory activities and manufacturing scale-up to move novel candidates from laboratory to clinic. The company operates multiple research centers and manufacturing facilities and emphasizes biopharma capabilities, including biologics and antibody-based therapies. Its pipeline spans early-stage discovery through late-stage clinical trials, targeting both established and emerging disease areas. Strategically, Eli Lilly emphasizes innovation in chronic and complex diseases, expanding patient access to new treatments and pursuing global commercialization. The company’s operations combine proprietary R&D, manufacturing infrastructure and global commercial teams to deliver therapies to healthcare providers and patients, while also engaging in partnerships and licensing to accelerate development and distribution.AI Generated. May Contain Errors. Read More Eli Lilly and Company Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreLLY MarketRank™: Eli Lilly and Company scored higher than 98% of companies evaluated by MarketBeat, and ranked 9th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingEli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 2 strong buy ratings, 23 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialEli Lilly and Company has a consensus price target of $1,218.33, representing about 23.2% upside from its current price of $988.76.Amount of Analyst CoverageEli Lilly and Company has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eli Lilly and Company's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth23.48% Earnings GrowthEarnings for Eli Lilly and Company are expected to grow by 23.48% in the coming year, from $35.82 to $44.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eli Lilly and Company is 35.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Eli Lilly and Company is 35.12, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.86.Price to Earnings Growth RatioEli Lilly and Company has a PEG Ratio of 1.09. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEli Lilly and Company has a P/B Ratio of 35.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eli Lilly and Company's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.84% of the float of Eli Lilly and Company has been sold short.Short Interest Ratio / Days to CoverEli Lilly and Company has a short interest ratio ("days to cover") of 2.23, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eli Lilly and Company has recently decreased by 3.11%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldEli Lilly and Company has a dividend yield of 0.69%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthEli Lilly and Company has been increasing its dividend for 11 years.Dividend CoverageThe dividend payout ratio of Eli Lilly and Company is 24.58%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 15.65% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.Read more about Eli Lilly and Company's dividend. News and Social Media4.4 / 5News Sentiment0.98 News SentimentEli Lilly and Company has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 142 news articles for Eli Lilly and Company this week, compared to 13 articles on an average week.Search Interest224 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 72% compared to the previous 30 days.MarketBeat Follows130 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 242% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eli Lilly and Company insiders have not sold or bought any company stock.Percentage Held by Insiders0.14% of the stock of Eli Lilly and Company is held by insiders.Percentage Held by Institutions82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eli Lilly and Company's insider trading history. Receive LLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LLY Stock News HeadlinesEli Lilly Is A Buy (Technical Analysis)2 hours ago | seekingalpha.comWatch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss PartyMay 18 at 9:11 PM | fool.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss PartyMay 18 at 8:45 PM | fool.comEli Lilly Stock: Next Stop $2,000?May 18 at 6:50 PM | fool.comWhat the FDA's Latest Proposal Means for Lilly, Novo, and HimsThe FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.May 7, 2026 | marketbeat.comLilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It PermanentEli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.May 1, 2026 | marketbeat.comViking Therapeutics Faces Timeline Risk—But Upside Could Be Huge (LLY)Viking Therapeutics stock faces near-term pressure, but its GLP-1 pipeline and clinical timeline could deliver significant long-term upside...May 1, 2026 | marketbeat.comSee More Headlines LLY Stock Analysis - Frequently Asked Questions How have LLY shares performed this year? Eli Lilly and Company's stock was trading at $1,075.00 on January 1st, 2026. Since then, LLY stock has decreased by 8.0% and is now trading at $988.76. How were Eli Lilly and Company's earnings last quarter? Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings results on Thursday, April, 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. Read the conference call transcript. Is Eli Lilly and Company buying back stock? Eli Lilly and Company's board authorized a share buyback plan on Monday, December 9th 2024, which allows the company to repurchase $15,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 2% of its shares through open market purchases. Shares buyback plans are often an indication that the company's management believes its stock is undervalued. Does Eli Lilly and Company have any subsidiaries? Eli Lilly and Company subsidiaries include Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and others. Who are Eli Lilly and Company's major shareholders? Top institutional shareholders of Eli Lilly and Company include PNC Financial Services Group Inc. (5.45%), Jennison Associates LLC (0.54%), Amundi (0.54%) and Dimensional Fund Advisors LP (0.41%). Insiders that own company stock include Lilly Endowment Inc, David A Ricks, Daniel Skovronsky, J Erik Fyrwald, Patrik Jonsson, Johna Norton, Jamere Jackson, Alonzo Weems, Donald A Zakrowski and Gabrielle Sulzberger. View institutional ownership trends. How do I buy shares of Eli Lilly and Company? Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eli Lilly and Company own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include Broadcom (AVGO), NVIDIA (NVDA), Meta Platforms (META), BlackRock (BLK), Salesforce (CRM), Chevron (CVX) and ServiceNow (NOW). Company Calendar Record date for 3/10 Dividend2/13/2026Ex-Dividend for 3/10 Dividend2/13/2026Dividend Payable3/10/2026Last Earnings4/30/2026Record date for 6/10 Dividend5/15/2026Ex-Dividend for 6/10 Dividend5/15/2026Today5/18/2026Dividend Payable6/10/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 8 days, LLY's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Large Cap Pharma Sub-IndustryPharmaceuticals Current SymbolNYSE:LLY CIK59478 Webwww.lilly.com Phone(317) 276-2000Fax317-276-4878Employees50,000Year Founded1876Price Target and Rating Average Price Target for Eli Lilly and Company$1,218.33 High Price Target$1,400.00 Low Price Target$850.00 Potential Upside/Downside+23.2%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$28.15 Trailing P/E Ratio35.12 Forward P/E Ratio27.60 P/E Growth1.09Net Income$20.64 billion Net Margins34.98% Pretax Margin43.08% Return on Equity105.77% Return on Assets23.76% Debt Debt-to-Equity Ratio1.26 Current Ratio1.50 Quick Ratio1.10 Sales & Book Value Annual Sales$65.18 billion Price / Sales14.29 Cash Flow$24.73 per share Price / Cash Flow39.98 Book Value$28.07 per share Price / Book35.22Miscellaneous Outstanding Shares941,740,000Free Float940,423,000Market Cap$931.15 billion OptionableOptionable Beta0.48 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NYSE:LLY) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eli Lilly and Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Eli Lilly and Company With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
